Condition
Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma
Estimated Enrollment: 40
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: NCI-2012-02414|CLB-30101|U10CA031946|CDR0000068938
Study First Received: October 11, 2001
Last Updated: January 15, 2013
Estimated Primary Completion Date: February 2006
Primary Outcome Measures:
Percentage of patients who remain failure-free|Tumor response rate|Toxicities, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0|Overall survival|Failure-free survival within patient subgroups defined in terms of epidermal growth factor receptor (EGFR) overexpression and cyclooxygenase-2 (COX-2) expression
Sponsors and Collaborators:
National Cancer Institute (NCI)
Website Link: https://ClinicalTrials.gov/show/NCT00025207
